Lim Lew
Vielight Inc., Toronto, ON, Canada.
Front Neurol. 2024 Aug 23;15:1407785. doi: 10.3389/fneur.2024.1407785. eCollection 2024.
This manuscript outlines a model of Alzheimer's Disease (AD) pathophysiology in progressive layers, from its genesis to the development of biomarkers and then to symptom expression. Genetic predispositions are the major factor that leads to mitochondrial dysfunction and subsequent amyloid and tau protein accumulation, which have been identified as hallmarks of AD. Extending beyond these accumulations, we explore a broader spectrum of pathophysiological aspects, including the blood-brain barrier, blood flow, vascular health, gut-brain microbiodata, glymphatic flow, metabolic syndrome, energy deficit, oxidative stress, calcium overload, inflammation, neuronal and synaptic loss, brain matter atrophy, and reduced growth factors. Photobiomodulation (PBM), which delivers near-infrared light to selected brain regions using portable devices, is introduced as a therapeutic approach. PBM has the potential to address each of these pathophysiological aspects, with data provided by various studies. They provide mechanistic support for largely small published clinical studies that demonstrate improvements in memory and cognition. They inform of PBM's potential to treat AD pending validation by large randomized controlled studies. The presentation of brain network and waveform changes on electroencephalography (EEG) provide the opportunity to use these data as a guide for the application of various PBM parameters to improve outcomes. These parameters include wavelength, power density, treatment duration, LED positioning, and pulse frequency. Pulsing at specific frequencies has been found to influence the expression of waveforms and modifications of brain networks. The expression stems from the modulation of cellular and protein structures as revealed in recent studies. These findings provide an EEG-based guide for the use of artificial intelligence to personalize AD treatment through EEG data feedback.
本手稿概述了阿尔茨海默病(AD)病理生理学的递进层次模型,从其起源到生物标志物的发展,再到症状表现。遗传易感性是导致线粒体功能障碍以及随后淀粉样蛋白和tau蛋白积累的主要因素,这些已被确定为AD的标志。除了这些积累之外,我们还探索了更广泛的病理生理学方面,包括血脑屏障、血流量、血管健康、肠脑微生物数据、类淋巴液流动、代谢综合征、能量不足、氧化应激、钙超载、炎症、神经元和突触损失、脑实质萎缩以及生长因子减少。介绍了一种治疗方法——光生物调节(PBM),它使用便携式设备将近红外光照射到选定的脑区。PBM有潜力解决上述每一个病理生理学方面的问题,各项研究提供了相关数据。这些数据为大量已发表的小型临床研究提供了机制支持,这些研究表明记忆和认知功能得到了改善。它们表明PBM在大型随机对照研究验证之前有治疗AD的潜力。脑电图(EEG)上脑网络和波形变化的呈现为利用这些数据作为应用各种PBM参数以改善结果的指导提供了机会。这些参数包括波长、功率密度、治疗持续时间、LED定位和脉冲频率。已发现以特定频率脉冲会影响波形的表达和脑网络的改变。这种表达源于最近研究中揭示的细胞和蛋白质结构的调节。这些发现为利用人工智能通过EEG数据反馈实现AD个性化治疗提供了基于EEG的指导。